Impact of calcineurin inhibitors on rat glioma cells viability
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Although kidney transplantation outcomes have improved dramatically after using calcineurin inhibitors (CNIs), CNI toxicity continues to be reported and the mechanism remains uncertain. Here, we investigated the neurotoxicity of CNIs by focusing on the viability of glioma cells. Methods: Glioma cells were treated with several concentrations of CNIs for 24 hours at 37°C and their cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Results: Exposure to 0, 0.25, 0.5, 2.5, 5.0, and 10.0 mM concentrations respectively showed 100%, 64.3%, 61.3%, 68.1%, 62.4%, and 68.6% cell viability for cyclosporine and 100%, 38.6%, 40.8%, 43.7%, 37.8%, and 43.0% for tacrolimus. The direct toxic effect of tacrolimus on glioma cell viability was stronger than that of cyclosporine at the same concentration. Conclusion: CNIs can cause neurological side effects by directly exerting cytotoxic effects on brain cells. Therefore, we should carefully monitor the neurologic symptoms and level of CNIs in kidney transplant patients.
Abstract
Background: Although kidney transplantation outcomes have improved dramatically after using calcineurin inhibitors (CNIs), CNI toxicity continues to be reported and the mechanism remains uncertain. Here, we investigated the neurotoxicity of CNIs by focusing on the viability of glioma cells. Methods: Glioma cells were treated with several concentrations of CNIs for 24 hours at 37°C and their cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Results: Exposure to 0, 0.25, 0.5, 2.5, 5.0, and 10.0 mM concentrations respectively showed 100%, 64.3%, 61.3%, 68.1%, 62.4%, and 68.6% cell viability for cyclosporine and 100%, 38.6%, 40.8%, 43.7%, 37.8%, and 43.0% for tacrolimus. The direct toxic effect of tacrolimus on glioma cell viability was stronger than that of cyclosporine at the same concentration. Conclusion: CNIs can cause neurological side effects by directly exerting cytotoxic effects on brain cells. Therefore, we should carefully monitor the neurologic symptoms and level of CNIs in kidney transplant patients.
참고문헌 (22)
- Pascual M, "Strategies to improve long-term outcomes after renal transplantation", N Engl J Med, 346, pp.580~590 (2002)
- Malvezzi P, "The safety of calcineurin inhibitors for kidney-transplant patients", Expert Opin Drug Saf, 14, pp.1531~1546 (2015)
- Burdmann EA, "Cyclosporine nephrotoxicity", Semin Nephrol, 23, pp.465~476 (2003)
- Naesens M, "Calcineurin inhibitor nephrotoxicity", Clin J Am Soc Nephrol, 4, pp.481~508 (2009)
- Anghel D, "Neurotoxicity of immunosuppressive therapies in organ transplantation", Maedica (Buchar), 8, pp.170~175 (2013)
- Senzolo M, "Neurologic complications after solid organ transplantation", Transpl Int, 22, pp.269~278 (2009)
- Besenski N, "Brain MR imaging abnormalities in kidney transplant recipients", AJNR Am J Neuroradiol, 26, pp.2282~2289 (2005)
- Coley SC, "Quantitative MR diffusion mapping and cyclosporine-induced neurotoxicity", AJNR Am J Neuroradiol, 20, pp.1507~1510 (1999)
- Schwartz RB, "Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases", AJR Am J Roentgenol, 165, pp.627~631 (1995)
- Oh YL, "Cyclosporine-induced apoptosis in osteosarcoma cells", Transplant Proc, 38, pp.2237~2239 (2006)
- Han SY, "Total antioxidant status and oxygen free radicals during hepatic regeneration", Transplant Proc, 38, pp.2214~2215 (2006)
- Hoorn EJ, "Pathogenesis of calcineurin inhibitor-induced hypertension", J Nephrol, 25, pp.269~275 (2012)
- Chakkera HA, "Calcineurin inhibition and new-onset diabetes mellitus after transplantation", Transplantation, 95, pp.647~652 (2013)
- Rosendal F, "Does chronic low-dose treatment with cyclosporine influence the brain? A histopathological study in pigs", Transplant Proc, 37, pp.3305~3308 (2005)
- Kiemeneij IM, "Acute headache as a presenting symptom of tacrolimus encephalopathy", J Neurol Neurosurg Psychiatry, 74, pp.1126~1127 (2003)
- Thompson CB, "Association between cyclosporin neurotoxicity and hypomagnesaemia", Lancet, 2, pp.1116~1120 (1984)
- Gijtenbeek JM, "Cyclosporine neurotoxicity: a review", J Neurol, 246, pp.339~346 (1999)
- Kou R, "Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A", J Biol Chem, 277, pp.29669~29673 (2002)
- Han SY, "Effects of cyclosporine and tacrolimus on the oxidative stress in cultured mesangial cells", Transplant Proc, 38, pp.2240~2241 (2006)
- Jang YH, "Polyphenol (-)-epigallocatechin gallate protection from ischemia", reperfusion-induced renal injury in normotensive and hypertensive rats, 2006, pp.38, 2190~2194
- Folbergrová J, "Changes in the bioenergetic state of rat hippocampus during 2.5 min of ischemia, and prevention of cell damage by cyclosporin A in hyperglycemic subjects", Exp Brain Res, 114, pp.44~50 (1997)
- Beal MF, "Mitochondrial dysfunction in neurodegenerative diseases", Biochim Biophys Acta, 1366, pp.211~223 (1998)